Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | DNM2 | P50570 | 7/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23258625 | 0.89 | DNM2 (0.49) | RAB9ANPC1MAPTGBA1TP53 | |
| SCHEMBL25858525 | 0.88 | SLC2A1 (0.51) | RAB9ANPC1MAPTGBA1TP53 | |
| SCHEMBL25858754 | 0.87 | NPC1 (0.50) | RAB9ANPC1MAPTGBA1TP53 | |
| SCHEMBL18037968 | 0.87 | RAB9A (0.46) | RAB9ANPC1MAPTGBA1TP53 | |
| SCHEMBL25858664 | 0.85 | KMT2A (0.47) | RAB9ANPC1MAPTTP53SMN1; SMN2 | |
| SCHEMBL18037988 | 0.85 | RAB9A (0.50) | RAB9ANPC1MAPTGBA1TP53 | |
| SCHEMBL25858903 | 0.85 | RAB9A (0.46) | RAB9ANPC1MAPTTP53SMN1; SMN2 | |
| SCHEMBL25858863 | 0.85 | RAB9A (0.53) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL23258633 | 0.84 | DNM2 (0.49) | RAB9ANPC1MAPTGBA1TP53 | |
| SCHEMBL25858631 | 0.84 | NPC1 (0.55) | RAB9ANPC1MAPTTP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2023-08-31 | — | — | US | disclosed |
| US-11691951-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691951-B2 | Inhibition of Olig2 activity | GLI2, ING2, GMFG | RAB9A 3638/4885NPC1 4224/4885MAPT 1722/4885 |
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | RAB9A 3638/4885NPC1 4224/4885MAPT 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.